Free Trial
→ Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:MREO

Mereo BioPharma Group Q4 2025 Earnings Report

Mereo BioPharma Group logo
$0.25 +0.01 (+4.00%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$0.25 +0.00 (+0.16%)
As of 05/8/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Mereo BioPharma Group EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.01
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Mereo BioPharma Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.30 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mereo BioPharma Group Announcement Details

Quarter
Q4 2025
Date
3/20/2026
Time
Before Market Opens
Conference Call Date
Thursday, March 26, 2026
Conference Call Time
3:00AM ET

Upcoming Earnings

Mereo BioPharma Group's Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled on Monday, May 11, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Mereo BioPharma Group's Q4 2025 Press ReleasePress Release
(6-K)
Mereo BioPharma Group's Q4 2025 Annual reportAnnual report
(10-K)

Mereo BioPharma Group Earnings Headlines

Mereo BioPharma Group (MREO) Expected to Announce Quarterly Earnings on Tuesday
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30769921
Mereo BioPharma Group plc Sponsored ADR
April 19, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/MREO
Massive Data Leak Exposes 512,000-Line Code That Could Change Society Forever
"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent traveled to Lower Manhattan for a sit-down interview with 60-year Wall Street legend Marc Chaikin, she was shocked to discover that Marc had prepared a live demonstration of a technology that could change society forever. It involves NASA, the Department of Defense, huge banks – and a MAJOR AI upgrade that could add $400 trillion to the global economy.tc pixel
May 10 at 1:00 AM  |  Chaikin Analytics (Ad)
We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely
April 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/were-hopeful-mereo-biopharma-group-133941496.html
Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & Korsinsky
April 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/06/3268658/3080/en/class-action-filed-against-mereo-biopharma-group-plc-mreo-april-6-2026-deadline-to-join-contact-levi-korsinsky.html
MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
April 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/06/3268642/673/en/mreo-deadline-today-rosen-global-investor-counsel-encourages-mereo-biopharma-group-plc-investors-to-secure-counsel-before-important-april-6-deadline-in-securities-class-action-mreo.html
See More Mereo BioPharma Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mereo BioPharma Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your email.

About Mereo BioPharma Group

Mereo BioPharma Group (NASDAQ:MREO) plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases. Additional clinical programs target oncology and immunology indications, leveraging both internally developed molecules and partnerships with third-party biotech and pharmaceutical companies. The company conducts multi‐center trials in Europe and North America, collaborating with academic institutions and contract research organizations to advance its clinical objectives.

Established in 2013 and headquartered in London, Mereo BioPharma has built a team with expertise in clinical development, regulatory affairs and corporate strategy to support its focused portfolio. The company’s business strategy emphasizes strategic alliances, out-licensing opportunities and selective acquisitions to enhance shareholder value and ensure sustained progress across its pipeline. Mereo is listed on the NASDAQ under the ticker symbol MREO and maintains operations in the United Kingdom, United States and Europe.

View Mereo BioPharma Group Profile
Earnings Tools